The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 4 November 2008, www.theannals.com, DOI 10.1345/aph.1L355.
The Annals of Pharmacotherapy: Vol. 42, No. 12, pp. 1908-1911. DOI 10.1345/aph.1L355
© 2008 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bird, M. L
Right arrow Articles by Vesta, K. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bird, M. L
Right arrow Articles by Vesta, K. S

Varenicline-Associated Acute Renal Failure

Matthew L Bird, PharmD

Internal Medicine Pharmacy Resident, Department of Pharmacy, Clinical Administrative Sciences, College of Pharmacy, University of Oklahoma, Oklahoma City, OK

Kimi S Vesta, PharmD BCPS

Associate Professor, Department of Pharmacy, Clinical Administrative Sciences, College of Pharmacy, University of Oklahoma

Reprints: Dr. Vesta, Department of Pharmacy, Clinical Administrative Sciences, College of Pharmacy, University of Oklahoma, 1110 N. Stonewall Ave., Oklahoma City, OK 73117, fax 405/271-6430, Kimi-Vesta{at}ouhsc.edu

OBJECTIVE: To report an association between acute renal failure and varenicline.

CASE SUMMARY: A 53-year-old white male with preexisting moderate renal insufficiency was admitted to the hospital for acute renal failure following a change in serum creatinine from 4 mg/dL at baseline to 10.6 mg/dL upon admission. One week prior to admission, the patient started taking varenicline (dose undetermined) for smoking cessation and had been stable on all other medications for 2 months prior to admission. All hospital workup tests were negative for prerenal azotemia, postrenal obstruction, and intrinsic renal disease. Varenicline was discontinued on admission. With no other changes in therapy, the serum creatinine level decreased each day of the patient's 5-day hospitalization to 8.6 mg/dL upon discharge, and it was 6.4 mg/dL at a follow-up appointment 2 weeks after discharge.

DISCUSSION: Varenicline is a novel medication that is effective for smoking cessation. Adverse effects are generally mild and self-limiting, with gastro-intestinal effects most commonly reported. According to the package insert, varenicline does not change creatinine clearance to any appreciable extent, but it should be used with caution in patients with renal impairment. It also states that varenicline can cause acute renal failure rarely; to our knowledge, this is the first published association of varenicline with renal effects. Use of the Naranjo probability scale showed varenicline to be the probable cause of renal dysfunction in this patient because of the temporal relationship and lack of alternative causes.

CONCLUSIONS: Although there was a probable relationship between varenicline and acute renal failure in this patient, the significant benefit of smoking cessation to overall health outweighs the risk of this rare adverse effect. Clinicians should be aware of this potential adverse effect and should monitor renal function upon initiation of varenicline therapy, especially in patients with chronic kidney disease.

Key Words: acute renal failure, varenicline

Published Online, November 4, 2008. www.theannals.com, DOI 10.1345/aph.1L355





homecopy help contact us subscription past issues search current issue
Copyright © 2008 by Harvey Whitney Books Company.